Wolfgang Plischke - Evotec AG Insider

Evotec AG -- USA Stock  

USD 20.35  0.00  0.00%

Chairman of the Supervisory Board

Prof. Dr. Wolfgang Plischke was Chairman of the Supervisory Board at Evotec AG since June 17, 2014. He is Chairman of the Remuneration and Nomination Committee at the Company. From March 2006 until April 2014 he was Member of the Board of Management of Bayer AG. He was responsible for Technology, Innovation and Sustainability and for the AsiaPacific region. From January 2002 to February 2006, he was Head of the Pharmaceuticals Business Group at Bayer AG with responsibility for the global business with prescription drugs. From 2000 to 2002, he served as Head of the Pharmaceuticals Business Group in North America at Bayer AG. From 1995 to 2000, Prof. Dr. Plischke served as President of Bayer Yakuhin Ltd., Japan, with responsibility for Pharmaceuticals and Consumer Care. He began his career in 1980 with Bayers subsidiary Miles Diagnostics after completing his biology studies at Hohenheim University. Prof. Dr. Plischke was Member of the Supervisory Board of Bayer AG since April 2016. He also holds a number of offices outside of Bayer AG. He is Member of the Board of the Walter Siegenthaler Society and the Robert Koch Foundation. He is also a Member of the senate of the Helmholtz association. In July 2011, Prof. Dr. Wolfgang Plischke was appointed honorary professor for Business Chemistry at the Ludwig Maximilian University of Munich.
Age: 64  Chairman Since 2014  Ph.D    
49 40 5 60 81 0  http://www.evotec.com
Wolfgang Plischke was Chairman of the Supervisory Board at Evotec AG since June 17, 2014. He is former member of the management board at Bayer AG.

Management Efficiency

The company has return on total asset (ROA) of 4.56 % which means that it generated profit of $4.56 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.13 % meaning that it generated $11.13 on every $100 dollars invested by stockholders.
The company has accumulated 213.13 M in total debt with debt to equity ratio (D/E) of 53.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.68 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG is traded on OTC Market in USA.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 1,238 people.

Did you try this?

Run Portfolio Quick Import Now

Portfolio Quick Import

Import or update all your transactions via one easy-to-use interface
Hide  View All  NextLaunch Portfolio Quick Import

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Evotec AG to your portfolio

Top Management

Evotec AG Leadership Team
Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance

Evotec AG Performance Indicators